Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12618000197235
Ethics application status
Approved
Date submitted
8/11/2017
Date registered
7/02/2018
Date last updated
23/12/2021
Date data sharing statement initially provided
8/01/2019
Date results information initially provided
10/12/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
A BLINDED, CONTROLLED STUDY OF THE VALUE OF OBJECTIVE MEASUREMENT IN TREATING PARKINSON’S DISEASE.
Query!
Scientific title
A BLINDED, CONTROLLED STUDY OF THE VALUE OF OBJECTIVE MEASUREMENT IN TREATING PARKINSON’S DISEASE.
Query!
Secondary ID [1]
293316
0
Nil
Query!
Universal Trial Number (UTN)
Nil
Query!
Trial acronym
Treat to Target
Query!
Linked study record
Nil
Query!
Health condition
Health condition(s) or problem(s) studied:
Parkinson's Disease
305403
0
Query!
Condition category
Condition code
Neurological
304686
304686
0
0
Query!
Parkinson's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
All participants will wear the Parkinson's Kinetigraph-watch for 7 days prior to the baseline visit and for any future visits. This will be organised by the Florey Study Team. The PKG-watch measures levels of bradykinesia and dyskinesia and provides a report ("the Parkinson's Kinetigraph- PKG"). Participants will be classified into one of two groups. They will then consult with the study doctor who will classify them as "controlled" or "uncontrolled" (based on their symptomatology) and treat them according to their expertise. In Group 1), the participant PKG is available to the doctor, the participant is treated with anti-PD medications according to the doctor's judgement; Group 2) No PKG is available and the participant is treated according to the doctor's judgement. This cycle continues until all participants are classed as "controlled" (to a maximum of 4 visits). The time between visits is approximately 1 month (i.e. each cycle is approximately 1month long).
Participants will be seen at the hospital clinics.
Intervention adherence will be assessed by the study team by only utilising participant data where it is evident the PKG has been worn for a minimum of 5 days.
Query!
Intervention code [1]
299575
0
Treatment: Devices
Query!
Comparator / control treatment
The control group is Group 2)- patient wears PKG for 7 days at the beginning and again at the end of their participation, however no PKG available to the doctor
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
330005
0
Severity of PD assessed using Total MDS-UPDRS scores.
Query!
Assessment method [1]
330005
0
Query!
Timepoint [1]
330005
0
4 months
Query!
Secondary outcome [1]
340396
0
Bradykinesia, dyskinesias and OFF time measured by the PKG.
Query!
Assessment method [1]
340396
0
Query!
Timepoint [1]
340396
0
4 months post study enrolment.
Query!
Secondary outcome [2]
342534
0
Measurement of quality of life symptoms as measured by the PDQ-39 assessment.
Query!
Assessment method [2]
342534
0
Query!
Timepoint [2]
342534
0
4 months post study enrolment.
Query!
Secondary outcome [3]
342796
0
Measurement of non-motor symptoms as measured by the SENS-PD assessment.
Query!
Assessment method [3]
342796
0
Query!
Timepoint [3]
342796
0
4 months post study enrolment..
Query!
Eligibility
Key inclusion criteria
- Parkinson's Disease duration of 3-12 years
- Taking 3 or more doses of levodopa a day
Query!
Minimum age
58
Years
Query!
Query!
Maximum age
76
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Contraindication to increasing dopaminergic medications (e.g. hallucinations, orthostatic hypotension, likely resistance to dopaminergic medication).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
N/A
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
N/A
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Participants will be allocated to one of the 2 treatment groups in the order in which they present.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
280 people will be recruited into the study. Power calculations/assumptions are based on pilot data.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
2/04/2018
Query!
Actual
5/06/2018
Query!
Date of last participant enrolment
Anticipated
3/06/2019
Query!
Actual
25/08/2019
Query!
Date of last data collection
Anticipated
20/12/2019
Query!
Actual
18/12/2019
Query!
Sample size
Target
280
Query!
Accrual to date
Query!
Final
209
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
9374
0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Query!
Recruitment hospital [2]
9897
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [3]
9898
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [4]
9900
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [5]
9901
0
Royal Melbourne Hospital - City campus - Parkville
Query!
Recruitment hospital [6]
12833
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [7]
12834
0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Query!
Recruitment hospital [8]
15444
0
Goulburn Valley Health - Shepparton campus - Shepparton
Query!
Recruitment hospital [9]
15499
0
Beach Brain Pty Ltd - Birtinya
Query!
Recruitment postcode(s) [1]
18063
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [2]
18704
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
18705
0
7000 - Hobart
Query!
Recruitment postcode(s) [4]
18707
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
18708
0
3050 - Parkville
Query!
Recruitment postcode(s) [6]
25302
0
2145 - Westmead
Query!
Recruitment postcode(s) [7]
25303
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [8]
28785
0
3630 - Shepparton
Query!
Recruitment postcode(s) [9]
28850
0
4575 - Birtinya
Query!
Funding & Sponsors
Funding source category [1]
297940
0
Other Collaborative groups
Query!
Name [1]
297940
0
Florey Neuroscience Institute
Query!
Address [1]
297940
0
30 Royal Parade, Parkville 3052 VIC
Query!
Country [1]
297940
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Florey Neuroscience Institute
Query!
Address
30 Royal Parade, Parkville 3052 VIC
Query!
Country
Australia
Query!
Secondary sponsor category [1]
297003
0
None
Query!
Name [1]
297003
0
Query!
Address [1]
297003
0
Query!
Country [1]
297003
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
298985
0
St Vincent's Hospital Melbourne
Query!
Ethics committee address [1]
298985
0
41 Victoria Parade, Fitzroy 3065 VIC
Query!
Ethics committee country [1]
298985
0
Australia
Query!
Date submitted for ethics approval [1]
298985
0
23/01/2018
Query!
Approval date [1]
298985
0
02/03/2018
Query!
Ethics approval number [1]
298985
0
Query!
Summary
Brief summary
The research project is testing a new way of managing Parkinson’s Disease. The new way of managing this involves the use of the Parkinson’s Kinetigraph (PKG) system, which includes a small, smart-watch like device that measures movements, worn on the wrist for 7 days.
In diseases such as diabetes or heart disease, “targets” exist (e.g. blood sugar levels, cholesterol levels) in order to obtain optimal health. We believe that by “measuring” Parkinson’s Disease using the PKG, we can develop targets around the movement problems in PD. These targets help us define whether a person with PD has controlled or uncontrolled movements. Previous research studies demonstrate that the PKG can identify uncontrolled symptoms and lead to changes which improve quality of life.
The aim of this project is to demonstrate that by utilising these targets, we can identify people with uncontrolled PD and treat them accordingly. If we can improve movement difficulties, we can hopefully improve quality of life.
Query!
Trial website
Nil
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
78898
0
Prof Malcolm Horne
Query!
Address
78898
0
Neurology Dept
St Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065
Query!
Country
78898
0
Australia
Query!
Phone
78898
0
+61414 817 562
Query!
Fax
78898
0
+6139231 3350
Query!
Email
78898
0
[email protected]
Query!
Contact person for public queries
Name
78899
0
Ms Holly Woodrow
Query!
Address
78899
0
Florey Institute of Neuroscience and Mental Health
PO Box 16085
Melbourne VIC 8007
Query!
Country
78899
0
Australia
Query!
Phone
78899
0
+61 439207518
Query!
Fax
78899
0
Query!
Email
78899
0
[email protected]
Query!
Contact person for scientific queries
Name
78900
0
Prof Malcolm Horne
Query!
Address
78900
0
Neurology Dept
St Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065
Query!
Country
78900
0
Australia
Query!
Phone
78900
0
+61414 817 562
Query!
Fax
78900
0
+6139231 3350
Query!
Email
78900
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This is not in line with the ethics approval given.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
Type
Is Peer Reviewed?
DOI
Citations or Other Details
Attachment
Study results article
Yes
Woodrow H, Horne MK, Fernando CV, Kotschet KE; Tre...
[
More Details
]
373960-(Uploaded-16-06-2021-12-30-21)-Journal results publication.pdf
Plain language summary
No
This study investigated whether the management of ...
[
More Details
]
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
A blinded, controlled trial of objective measurement in Parkinson's disease.
2020
https://dx.doi.org/10.1038/s41531-020-00136-9
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF